Post Covid-19 Scenario Analysis:
- ·
The
Covid-19 pandemic impacted the global diabetic nephropathy market negatively
because most priority was given to Covid-19 patients for treatment. Many
medical colleges and hospitals were restructured to accommodate more patients
diagnosed with Covid-19.
- · Dialysis and transplant of kidney operation in diabetic nephropathy patient were postponed and home care setting care was preferred.
- · Discovery and development of diabetic nephropathy medicines also slowed down during the pandemic, owing to the implementation of global lockdown which led to halt all operations.
- ·
Nevertheless, the market recovered steadily
in the post-pandemic, due to increased
investment in both the public and private sectors.
Segmentation:
The global diabetic nephropathy
market based on drugs class, type,
distribution channel, and region. The report discusses segments and
their sub-segments in detail with the help of tables and figures. Market
players and investors can strategize according to the highest
revenue-generating and fastest-growing segments mentioned in the report.
Based on drugs class, the angiotensin-converting enzyme inhibitors segment contributed to nearly one-third of the total market revenue in 2021, and is projected to lead the trail by 2031, owing to rise in number of temporary as well as permanent chronic heart disease, heart attack, hypertension, and diabetic nephropathy. Based on type, the Type-2 diabetes segment was the largest in 2021, accounting for nearly four-fifths of the total market revenue, and is projected to lead the trail by 2031. Based on distribution channel, the drug stores & retail pharmacy segment accounted for the highest share in 2021, holding more than half of the global market, and is expected to continue its leadership status during the forecast period, owing to increase in geriatric population.
North America held the largest share in 2021, contributing to more than
two-fifths of the total market share, and is projected to maintain its dominant
share in terms of revenue in 2031, owing to increase in number of patient
admissions and chronic kidney diseases. In addition, the Asia-Pacific region would manifest the fastest CAGR of
7.3% throughout the forecast period, owing to surge in number of
diabetic nephropathy cases, chronic heart disease cases, and increase in
prevalence of hypertension. The
other provinces studied in the report include Europe and LAMEA.
Leading Market Players: Leading market players of the global diabetic nephropathy market analyzed in the research include
- Abbott Laboratories,
- AbbVie Inc.,
- AstraZeneca Plc,
- Bayer Ag,
- Eli Lilly and Company,
- Merck & Co, Inc.,
- Novartis Ag,
- Pfizer Inc.,
- Reata Pharmaceuticals, Inc.,
- Sanofi.
These
players have adopted different strategies such as new product launches, collaborations,
expansion, joint ventures, agreements, and others to increase their market
share and maintain dominant shares in different regions. The report is valuable
in highlighting business performance, operating segments, product portfolio,
and strategic moves of market players to showcase the competitive
scenario.
Report Coverage | Details |
Forecast Period | 2022–2031 |
Base Year | 2021 |
Market Size in 2021 | $1.9 billion |
Market Size in 2031 | $3.3 billion |
CAGR | 6.0% |
No. of Pages in Report | 266 |
Segments covered | Drugs Class, Type, Distribution Channel, and Region. |
Drivers | Surge in number of geriatric populations suffering from diabetic nephropathy |
Continuous increase in range of conditions that can be treated by diabetic nephropathy medicine | |
Rise in demand of anti-diabetic medicine | |
Opportunities | Rise in incidence rates of various kidney diseases and rise in testing |
Restraints | Lack of skilled professionals for treatment of diabetic nephropathy in emerging and less developed countries |
Poor planning of diabetic nephropathy treatment in low-income countries |
0 Comments